Rocket Pharmaceuticals Inc (RCKT) Stock Price, Quote & News

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inher...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 659 8001

Website: www.rocketpharma.com

Address:

9 Cedarbrook Drive, Cranbury, United States

Stephanovich7654568 Dec. 6 at 4:14 PM

$RCKT XBI has nothing to do with the tax losses. RCKT were $14 a year ago. There is your tax losses. 🤣🤣🤣

0 · Reply

pjapak Dec. 4 at 8:07 PM

$RCKT I think XBI has neutralized tax loss period. This won't go down again below 3.

0 · Reply

Shinebox09 Dec. 4 at 1:31 PM

$RCKT back to $4

1 · Reply

HedgeAlerts Dec. 4 at 7:31 AM

Hedge Alert Live - Protect Your Portfolio Contract: $RCKT $2.50 Put · DEC 19, 2025 Exp Entry Price: $0.08 - $0.15 Exit Price Target: $0.11 Profit Margin: +38% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

xXCronoSXx Dec. 3 at 10:52 PM

$RCKT price Target mid 2026?

1 · Reply

kikmontero Dec. 3 at 8:08 PM

$RCKT Added more

0 · Reply

Shinebox09 Dec. 2 at 9:03 PM

$RCKT tomorrow back to $3.50

0 · Reply

chezki Dec. 2 at 6:02 PM

$RCKT a screenshot from one of the reviews!

3 · Reply

chezki Dec. 2 at 6:00 PM

$RCKT

0 · Reply

chezki Dec. 2 at 5:57 PM

$RCKT this is from glass door workers reviews! a realy bad sign for a start up!

1 · Reply

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 4:00 PM EST - 4 weeks ago

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Oct 14, 2025, 2:27 PM EDT - 7 weeks ago

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock

Oct 14, 2025, 7:00 AM EDT - 7 weeks ago

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Oct 10, 2025, 4:00 PM EDT - 2 months ago

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 7:11 AM EDT - 2 months ago

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Sep 9, 2025, 12:36 PM EDT - 3 months ago

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 28, 2025, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 20, 2025, 11:02 AM EDT - 3 months ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Aug 20, 2025, 9:31 AM EDT - 3 months ago

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

Aug 20, 2025, 7:09 AM EDT - 3 months ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Aug 20, 2025, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Aug 8, 2025, 2:16 PM EDT - 4 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Aug 7, 2025, 4:15 PM EDT - 4 months ago

Rocket (RCKT) Q2 Loss Narrows 16%

Aug 7, 2025, 4:00 PM EDT - 4 months ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Jul 30, 2025, 6:29 PM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 30, 2025, 11:07 AM EDT - 4 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE NTLA QURE

Jul 29, 2025, 10:26 AM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 25, 2025, 3:02 PM EDT - 4 months ago

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

Jul 24, 2025, 4:02 PM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT

Jul 24, 2025, 7:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Jul 17, 2025, 7:00 AM EDT - 5 months ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Jul 11, 2025, 10:25 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 9, 2025, 5:16 PM EDT - 5 months ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jul 7, 2025, 9:00 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

Jun 30, 2025, 7:00 AM EDT - 5 months ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Stephanovich7654568 Dec. 6 at 4:14 PM

$RCKT XBI has nothing to do with the tax losses. RCKT were $14 a year ago. There is your tax losses. 🤣🤣🤣

0 · Reply

pjapak Dec. 4 at 8:07 PM

$RCKT I think XBI has neutralized tax loss period. This won't go down again below 3.

0 · Reply

Shinebox09 Dec. 4 at 1:31 PM

$RCKT back to $4

1 · Reply

HedgeAlerts Dec. 4 at 7:31 AM

0 · Reply

xXCronoSXx Dec. 3 at 10:52 PM

$RCKT price Target mid 2026?

1 · Reply

kikmontero Dec. 3 at 8:08 PM

$RCKT Added more

0 · Reply

Shinebox09 Dec. 2 at 9:03 PM

$RCKT tomorrow back to $3.50

0 · Reply

chezki Dec. 2 at 6:02 PM

$RCKT a screenshot from one of the reviews!

3 · Reply

chezki Dec. 2 at 6:00 PM

$RCKT

0 · Reply

chezki Dec. 2 at 5:57 PM

$RCKT this is from glass door workers reviews! a realy bad sign for a start up!

1 · Reply

Drashkawisha Dec. 2 at 4:26 PM

$RCKT The post-CRL selloff was overdone. The fundamentals of the gene therapy pipeline haven't changed. Accumulating in this zone before the narrative shifts back to growth

0 · Reply

Grenville1 Dec. 2 at 3:25 PM

$RCKT The main takeout for me was towards the end where he confirmed that pretty much all their pipeline of treatments are Priority Review Voucher (PRV) eligible.

0 · Reply

Chickenforyou Dec. 2 at 2:57 PM

$RCKT anyone have link to conference?

2 · Reply

Drashkawisha Dec. 2 at 2:16 PM

$RCKT

0 · Reply

oaksapollo Dec. 2 at 1:17 PM

$RCKT regarding the PDUFA, he says “we checked every single box.” Sounds like they are very confident in Kresladi approval.

1 · Reply

Chickenforyou Dec. 2 at 4:38 AM

$RCKT will this stock double or triple Tomorrow?

1 · Reply

Stephanovich7654568 Dec. 2 at 12:26 AM

$RCKT Investors confrence = Dilution

0 · Reply

HedgeAlerts Dec. 1 at 10:24 PM

Hedge Alert Live - Protect Your Portfolio Contract: $RCKT $2.50 Put · DEC 19, 2025 Exp Entry Price: $0.08 - $0.15 Exit Price Target: $0.14 Profit Margin: +79% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Shinebox09 Dec. 1 at 8:51 PM

$RCKT horrible day

0 · Reply

Shinebox09 Dec. 1 at 7:44 PM

$RCKT 9 percent down what happened

0 · Reply

Bellz22 Dec. 1 at 7:39 PM

$RCKT added more 😈

0 · Reply

Shinebox09 Dec. 1 at 3:06 PM

$RCKT ouch all gains gone

1 · Reply

Market Cap	359.30M
Revenue (ttm)	0.00
Net Income (ttm)	-258.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,095,300
Avg Vol	2,404,874
Day's Range	N/A - N/A
Shares Out	108.22M
Stochastic %K	73%
Beta	0.66
Analysts	Sell
Price Target	$7.95